Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma

被引：16

作者：

von Tresckow, Bastian ^{[1
,2
]}

Fanale, Michelle ^{[3
,13
]}

Ardeshna, Kirit M. ^{[4
]}

Chen, Robert ^{[5
]}

Meissner, Julia ^{[6
]}

Morschhauser, Franck ^{[7
]}

Moskowitz, Craig ^{[8
,14
]}

Zinzani, Pier Luigi ^{[9
]}

Giezek, Hilde ^{[10
]}

Balakumaran, Arun ^{[11
]}

Vo, Thao T. ^{[11
]}

Raut, Monika ^{[11
]}

Brice, Pauline ^{[12
]}

机构：

[1] Univ Cologne, Fac Med, Dept Internal Med 1, Cologne, Germany

[2] Univ Hosp Cologne, Cologne, Germany

[3] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

[4] Univ Coll London Hosp, London, England

[5] City Hope Natl Med Ctr, Dept Hematol, 1500 E Duarte Rd, Duarte, CA 91010 USA

[6] Univ Hosp Heidelberg, Dept Internal Med 5, Heidelberg, Germany

[7] CHRU Lille, Hop Claude Huriez, Lille, France

[8] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, 1275 York Ave, New York, NY 10021 USA

[9] Univ Bologna, Inst Hematol L&A Seragnoli, Bologna, Italy

[10] MSD, Brussels, Belgium

[11] Merck & Co Inc, Kenilworth, NJ USA

[12] Hop St Louis, AP HP, Dept Hematol, Paris, France

[13] Seattle Genet, Bothell, WA USA

[14] Univ Miami Hlth Syst, Sylvester Comprehens Canc Ctr, Miami, FL USA

来源：

LEUKEMIA & LYMPHOMA | 2019年 / 60卷 / 11期

关键词：

Classical Hodgkin lymphoma; health-related quality-of-life; KEYNOTE-087; patient-reported outcomes; pembrolizumab; CANCER; PD-L1; EQ-5D; EORTC;

D O I：

10.1080/10428194.2019.1602262

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In KEYNOTE-087, pembrolizumab had a 69% overall response rate and acceptable safety in patients with relapsed/refractory classical Hodgkin lymphoma (rrHL). We assessed health-related quality of life (HRQoL) in KEYNOTE-087. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (QLQ-C30) and the EuroQoL Five Dimensions Questionnaire 3-level version (EQ-5D) were administered to 206 patients across three cohorts defined by lymphoma progression after: (1) autologous stem cell transplantation (ASCT) and subsequent brentuximab vedotin (BV) (n = 69); (2) salvage chemotherapy and BV (n = 79); and (3) ASCT without post-transplantation BV (n = 58). Compliance/completion rates were >= 90% at week 12 and >= 70% at week 24. QLQ-C30 global health status/QoL and EQ-5D visual analog scale scores showed mean increases from baseline in overall health at all assessed timepoints. With few exceptions, mean improvements from baseline to weeks 12 and 24 in QLQ-C30 functional and symptom scores occurred in all cohorts.

引用

页码：2705 / 2711

页数：7

共 50 条

[21] Impact of assessment frequency of patient-reported outcomes: an observational study using an eHealth platform in cancer patients
Pasquale F. Innominato
Sandra Komarzynski
Robert Dallmann
Nicholas I. Wreglesworth
Mohamed Bouchahda
Abdoulaye Karaboué
Ayhan Ulusakarya
Christian P. Subbe
David Spiegel
Francis A. Lévi
Supportive Care in Cancer, 2021, 29 : 6167 - 6170
[22] Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma
Maruyama, Dai
Hatake, Kiyohiko
Kinoshita, Tomohiro
Fukuhara, Noriko
Choi, Ilseung
Taniwaki, Masafumi
Ando, Kiyoshi
Terui, Yasuhito
Higuchi, Yusuke
Onishi, Yasushi
Abe, Yasunobu
Kobayashi, Tsutomu
Shirasugi, Yukari
Tobinai, Kensei
CANCER SCIENCE, 2017, 108 (05) : 1007 - 1012
[23] Patient-reported outcomes in patients with hematological relapse or progressive disease: a longitudinal observational study
Mia Sommer
Lene Kongsgaard Nielsen
Lars Børty Nielsen
Rasmus Froberg Brøndum
Marlene Maria Nielsen
Anne Stoffersen Rytter
Charles Vesteghem
Marianne Tang Severinsen
Tarec Christoffer El-Galaly
Martin Bøgsted
Mette Grønkjær
Lone Jørgensen
Health and Quality of Life Outcomes, 19
[24] Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108
O'Donnell, Peter H.
Arkenau, Hendrick Tobias
Sridhar, Srikala S.
Ong, Michael
Drakaki, Alexandra
Spira, Alexander, I
Zhang, Jingsong
Gordon, Michael S.
Degboe, Arnold N.
Gupta, Ashok K.
Mukhopadhyay, Pralay
Huang, Wenmei
Abdullah, Shaad E.
Angra, Natasha
Roskos, Lorin K.
Guo, Xiang
Friedlander, Terence
CANCER, 2020, 126 (02) : 432 - 443
[25] Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the randomized Phase II PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab
Reck, Martin
Granados, Ana Laura Ortega
de Marinis, Filippo
Meyers, Oren
Shen, Qin
Cho, Lillian
Stjepanovic, Neda
Boklage, Susan
EUROPEAN JOURNAL OF CANCER, 2024, 212
[26] Hypoglycaemic episodes in patients with type 2 diabetes - risk factors and associations with patient-reported outcomes: The PANORAMA Study
Simon, D.
de Pablos-Velasco, P.
Parhofer, K. G.
Goender-Frederick, L.
Lomon, I. Duprat
Vandenberghe, H.
Eschwege, E.
Bradley, C.
DIABETES & METABOLISM, 2015, 41 (06) : 470 - 479
[27] Magnetic Resonance-guided Stereotactic Radiotherapy for Localized Prostate Cancer: Final Results on Patient-reported Outcomes of a Prospective Phase 2 Study
Tetar, Shyama U.
Bruynzeel, Anna M. E.
Oei, Swie S.
Senan, Suresh
Fraikin, Tamara
Slotman, Berend J.
van Moorselaar, R. Jeroen A.
Lagerwaard, Frank J.
EUROPEAN UROLOGY ONCOLOGY, 2021, 4 (04): : 628 - 634
[28] Improvements in Patient-Reported Outcomes in Relapsed or Refractory Large B-Cell Lymphoma Patients Treated With Epcoritamab
Phillips, Tycel
Lugtenburg, Pieternella
Kalsekar, Anupama
Mutebi, Alex
Wang, Anthony
Blaedel, Julie
Kosa, Katherine
Martin, Susan
Sacchi, Mariana
Kilavuz, Nurgul
Thieblemont, Catherine
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (03): : e78 - e87.e2
[29] Nivolumab Treatment Beyond Investigator-Assessed Progression: Outcomes in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma From the Phase 2 CheckMate 205 Study
Cohen, J. B.
Engert, A.
Ansell, S. M.
Younes, A.
Trneny, M.
Savage, K. J.
Ramchandren, R.
Collins, G. P.
Fanale, M. A.
Armand, P.
Zinzani, P. L.
de Boer, J. P.
Shipp, M. A.
Santoro, A.
Timmerman, J. M.
Sacchi, M.
Sy, O.
Kuruvilla, J.
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 : 87 - 88
[30] Patient-Reported Outcomes and Impact of Type 2 Diabetes: A Cross-Sectional Study in the Kingdom of Saudi Arabia
Gelhorn, Heather L.
Boye, Kristina S.
Shalhoub, Huda
Matza, Louis S.
Jordan, Jessica B.
Alhammad, Ali
Anand, Savita B.
Ekhzaimy, Aishah A.
Strizek, Alena
PATIENT PREFERENCE AND ADHERENCE, 2020, 14 : 2231 - 2242

← 1 2 3 4 5 →